- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04564001
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis (INTOReTAK)
September 21, 2020 updated by: Assistance Publique - Hôpitaux de Paris
Takayasu arteritis (TA) is a vasculitis of unknown origin, resulting in progressive thickening and stenosis of large and medium arteries (the aorta and its major branches, and the pulmonary arteries).
First line therapy of TA consists of high dose corticosteroids (CS).
Between 20 and 50% of cases respond to CS alone, with subsequent resolution of symptoms and stabilization of vascular abnormalities.
Although second-line agents (methotrexate, azathioprine, mercaptopurine, mycophenolate mofetil) may result in initial remission, relapses remain common when prednisone is tapered.
Thus, 50% of CS-resistant or relapsing TA patients may achieve sustained remission with the addition of methotrexate.
During the last decade, biologics such as anti-tumor necrosis factor alpha (anti-TNFα) and anti-interleukin-6 (anti-IL-6) have been used as third-line treatment in refractory or relapsing TA.
Almost 90% of CS-methotrexate resistant TA cases responded to infliximab, an anti-TNFα, and sustained remission was obtained in 37 to 76% of the cases.
Tocilizumab, an anti-IL-6 has given similar results with 68% of sustained remission in refractory TA.
Irrespective of classical cardiovascular risk factors, the systemic inflammation and CS use play a pivotal role in the occurrence of cardiovascular thrombotic events (CVEs).
As CVEs overlap with TA complications it is primordial to drastically taper CS in that vasculitis.
We therefore hypothesize that Infliximab or Tocilizumab can achieve a remission in more than 70% of refractory/relapsing TA cases to CS associated to a second-line agent.
INTOReTAK, first randomized prospective study in TA, has an original design testing Infliximab and Tocilizumab propensity to achieve over 70% of sustained remission in refractory/relapsing TA and evaluating jointly the 2 arms.
The primary objective of this study is to obtain, by arm, ≥ 70% of patients at 6 months after randomization with prednisone ≤ 0.1mg/kg per day and inactive disease (NIH score ≤ 1) during the last 3 months.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tristan MIRAULT
- Phone Number: +33156093051
- Email: tristan.mirault@aphp.fr
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Diagnosis of Takayasu disease according to the international criteria of the American College of Rheumatology (ACR)
- Age at disease onset < 40 years
- Claudication of extremities
- Decreased brachial artery pulse (one or both arteries)
- Blood pressure difference of >10mm Hg between the arms
- Bruit over subclavian arteries or aorta
- Active disease according to the international criteria of the National Institute of Health (NIH)
New onset or worsening of at least two of the following four criteria
- Systemic features
- Elevated erythrocyte sedimentation rate
- Features of vascular ischemia or inflammation
- Typical angiographic features
Refractory/relapsing disease
- Failure of disease to respond to daily corticosteroids therapy (1mg/kg/day for > 1month), i.e. disease still active
- Inability to taper corticosteroids below 10mg/day within 6 months
- Inability to discontinue corticosteroids after 1 year of treatment
- Relapse of disease after gradual decrease of corticosteroids therapy
- Patients with one immunosuppressive agent (methotrexate, azathioprine, mercaptopurine or mycophenolate mofetil)
- Age of 18 years or older
- Weight 40 - 120 kg
- Medical follow-up in a university or general hospital in France
- Social insurance
- Willing and able to provide written informed consent
- Willing and able to comply with treatment and follow-up procedures required by the study protocol
- For female subjects of child-bearing age, a negative serum pregnancy test and no pregnancy plans within 12 months
- For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to Screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, or condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence.
- Chest X-ray results (postero-anterior and lateral) within 12 weeks prior to enrollment with no evidence of active tuberculosis, active infection, or malignancy
Tuberculosis assessment:
- Active Tuberculosis infection treatment achieved
- Completion of at least 3 weeks treatment for Latent Tuberculosis infection
- Negative tuberculin skin test (TST) or interferon-gamma release assay (IGRA) (e.g., QuantiFERON®-TB Gold or T-spot TB® Test)
Exclusion Criteria:
- Active tuberculosis or untreated latent tuberculosis
- Evidence of active infection (includes chronic infection)
- Infection requiring treatment with antibiotics within 2 weeks prior to enrollment
- Infection with human immunodeficiency virus (HIV), hepatitis C, or a positive hepatitis B surface antigen.
- Pregnancy or lactation
- Inability to comply with study guidelines
- Inability to provide informed consent
- Immunosuppressant type or dose modification within 30 days prior to enrollment
- Alcohol or drug abuse, that, in the investigator's opinion, could prevent a subject from fulfilling the study requirements or that would increase the risk of study procedures
- Severe renal insufficiency (creatinine clairance <30mL/min/1,73m2)
- Hepatic dysfunction as shown by aspartate transaminase (AST) or alanine transaminase (ALT) levels >5-fold the upper limit of normal
- Heart failure ≥ stage III / IV NYHA,
- History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin, or solid tumors treated with curative therapy and disease free for at least 5 years.
- History of multiple sclerosis and/or demyelinating disorder
- History of severe allergic or anaphylactic reactions to infliximab, any chimeric murine monoclonal antibody, tocilizumab, and their respective excipients or prednisone
- History of immediate hypersensitivity reaction to iodinated and gadolinium-based contrast media
- Cytopenia: Hemoglobin < 8.5 g/dL, absolute neutrophil < 1.5 G/L, Platelet count < 80 G/L
- Any live (attenuated) vaccine fewer than 4 weeks before enrolment. Recombinant or killed virus vaccines fewer than 2 weeks before enrolment.
Use of the following systemic treatments during the specified periods
- Treatment with biologic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, anakinra, tocilizumab, etanercept, abatacept, ixekizumab, secukinumab, ustekinumab, alemtuzumab) within 6 months prior to enrollment
- Past treatment with rituximab within the past 12 months, or past treatment with rituximab more than 12 months ago where the B lymphocytes count has not returned to normal at time of enrollment
- Treatment with any systemic alkylating agents within 6 months prior to enrollment (e.g., cyclophosphamide, chlorambucil)
- Lack of affiliation to a social security benefit plan (as a beneficiary or assignee)
Presence of any of the following disease processes:
- Microscopic polyangiitis
- Granulomatosis with polyangiitis
- Eosinophilic granulomatosis with polyangiitis
- Polyarteritis nodosa
- Cogan's syndrome
- Behcet's disease
- Sarcoidosis
- Kawasaki's disease
- Atypical mycobacterial infections
- Deep fungal infections
- Lymphoma, lymphomatoid granulomatosis, or other type of malignancy tha mimics vasculitis
- Cryoglobulinemic vasculitis
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Mixed connective tissue disease or any overlap autoimmune syndrome
- Known constitutive immunodeficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A ( Infliximab)
Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
|
Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
|
Experimental: B (Tocilizumab)
Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
|
Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with prednisone ≤ 0.1mg/kg per day and sustained inactive disease (NIH score ≤ 1) from M3 to M6 and same biological therapy from randomization
Time Frame: at 6 months after randomization
|
at 6 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of relapse as defined by the NIH criteria
Time Frame: between 3 and 6 months
|
between 3 and 6 months
|
|
Incidence of traitement failure
Time Frame: at 3 months after randomization
|
Traitment failure will be defined as disease still active according to the NIH criteria
|
at 3 months after randomization
|
Incidence of revascularization procedures
Time Frame: at 6 months after randomization
|
at 6 months after randomization
|
|
Incidence of revascularization procedures
Time Frame: at 12 months after randomization
|
at 12 months after randomization
|
|
Cumulative doses of prednisone
Time Frame: at 6 months after randomization
|
at 6 months after randomization
|
|
Cumulative doses of prednisone
Time Frame: at 12 months after randomization
|
at 12 months after randomization
|
|
Incidence of adverse events of grades III and IV
Time Frame: at 6 months after randomization
|
at 6 months after randomization
|
|
Incidence of adverse events of grades III and IV
Time Frame: at 12 months after randomization
|
at 12 months after randomization
|
|
Quality of life will be assessed using the SF36 questionnaire
Time Frame: at 6 months
|
at 6 months
|
|
Quality of life
Time Frame: at 12 months
|
Quality of life will be assessed using the SF36 questionnaire
|
at 12 months
|
Proportion of new vascular lesions
Time Frame: at 6 months
|
at 6 months
|
|
Proportion of new vascular lesions
Time Frame: at 12 months
|
at 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2020
Primary Completion (Anticipated)
February 1, 2021
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
September 21, 2020
First Submitted That Met QC Criteria
September 21, 2020
First Posted (Actual)
September 25, 2020
Study Record Updates
Last Update Posted (Actual)
September 25, 2020
Last Update Submitted That Met QC Criteria
September 21, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P160909
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Takayasu Arteritis
-
Assistance Publique - Hôpitaux de ParisChugai PharmaceuticalCompleted
-
Instituto Nacional de Cardiologia Ignacio ChavezCompleted
-
AbbVieActive, not recruitingTakayasu Arteritis (TAK)Argentina, Brazil, China, Japan, Korea, Republic of, Turkey
-
Assistance Publique - Hôpitaux de ParisRecruitingArteritis | Systemic Vasculitis | Arteritis, TakayasuFrance
-
Chinese Pulmonary Vascular Disease Research GroupRecruitingTakayasu Arteritis With Pulmonary Artery Involvement | Percutaneous Transluminal Pulmonary Angioplasty | PAH Targeted MedicationChina
-
Beijing Institute of Heart, Lung and Blood Vessel...Peking University People's Hospital; Shanghai Zhongshan HospitalRecruiting
-
University of Sao PauloFederal University of São PauloUnknown
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedTakayasu's ArteritisUnited States, Canada
-
Seoul National University HospitalUnknownTakayasu's ArteritisKorea, Republic of
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
PfizerCompleted
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
Asan Medical CenterNot yet recruitingCrohn Disease | Therapeutic Drug Monitoring | Infliximab | Perianal Fistula Due to Crohn's Disease | Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus